中新网广州11月13日电(王华 晓雷)来自中华医学研究会的数据称，中国肿瘤患者五年生存率仅22%，该学会肝病委员会13日开通首条公益热线，帮助患者求医、规范治疗。

Guangzhou local fars news agency reported on November 13 (Reuters)(XiaoLei wang hua)From the data of the medical research council in said,Chinese cancer patients 5 years of survival rate is only 22%,The academy liver disease committee 13 opened first public hotline,Help patients healed/Standardized treatment.

　　中华医学研究会肝病委员会副主任委员王洪剑说，中国肿瘤患者生存率低主要原因是发现太迟、求医过程中出现错误以及恐惧情绪影响病人免疫系统。多数患者对医疗知识和行业不了解，面对铺天盖地的信息的往往无助乱投医，导致浪费金钱、耽误病情。

The Chinese medicine research institute liver disease committee member, deputy director of the WangHongJian said,Chinese cancer patients survival rate low main reason is found too late/Seek medical advice appeared in the process of error and fear emotions affect patient the immune system.The majority of patients for medical knowledge and industry do not understand,In the face of the deluge of information often helpless disorderly TouYi,Lead to waste of money/Delay an illness.

　　中华医学研究会肝病委员会今天开通公益热线4009991700，帮助患者了解并找到规的医院和最合适医生，免费建立健康档案、跟踪随访、组织专家会诊等，与此同时也为中国制定大众版肿瘤防治指南提供临床数据。

The Chinese medicine research institute liver disease committee today opened public hotline at 4009991700,Help patients understand and find the gauge of the hospitals and the most appropriate doctor,Free to establish health files/Tracking follow-up/Organization expert consultation, etc,At the same time also for the formulation of China public version of cancer prevention and control guide provide clinical data.

　　王洪剑称，其实现在治疗技术已今非昔比，癌症已不是不治之症而是一种慢性病。现如今有多种医疗手段可以控制肿瘤病情甚至彻底清除癌细胞，直至康复，例如细胞免疫疗法已经被公认为继手术、化疗、放疗之后的第四种最活跃、最有发展前途的一种肿瘤治疗方法。

WangHongJian says,In fact now treatment technology has is not what it was,Cancer is not fatal disease but a kind of chronic disease.Nowadays there are many medical method can control the illness even eradicate tumor cells,Until recovery,Such as cellular immune therapy has already been accepted generally as following surgery/chemotherapy/After radiotherapy the fourth most active/The most promising a tumor treatment.

　　据王洪剑介绍，细胞免疫治疗技术适用于包括肝癌、肺癌、鼻咽癌多种实体肿瘤。临床实践显示使用该治疗技术的肿瘤患者3年生存率为72%，未使用的为33%；5年生存率为67%，未使用的为22%。均。完

According to WangHongJian introduced,Cellular immune treatment technology suitable for hepatocellular carcinoma/Lung cancer/Nasopharyngeal carcinoma a variety of solid tumors.Clinical practice shows that using the treatment technology of tumor patients with a 3-year survival of 72%,Not used for 33%;5 years of survival rate was 67%,Not used for 22%.are.finish